share_log

Novavax | 4: Statement of changes in beneficial ownership of securities-Officer O'Hara Elaine

Novavax | 4: Statement of changes in beneficial ownership of securities

諾瓦瓦克斯醫藥 | 4：持股變動聲明
SEC announcement ·  03/26 19:05
Moomoo AI 已提取核心訊息
Elaine O'Hara, EVP, Chief Strategy Officer at Novavax, Inc. [NVAX], was reported to have engaged in a transaction involving the company's stock on March 1, 2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and the total value of shares, were not disclosed in the announcement. The action type and status of the transaction were also not provided. This information is critical for investors to understand the potential impact on their investment in Novavax.
Elaine O'Hara, EVP, Chief Strategy Officer at Novavax, Inc. [NVAX], was reported to have engaged in a transaction involving the company's stock on March 1, 2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and the total value of shares, were not disclosed in the announcement. The action type and status of the transaction were also not provided. This information is critical for investors to understand the potential impact on their investment in Novavax.
據報道，Novavax, Inc. [NVAX] 執行副總裁兼首席戰略官伊萊恩·奧哈拉於2024年3月1日參與了一項涉及該公司股票的交易。公告中未披露該交易的具體細節，包括股票數量、股票性質、交易價格和股票總價值。也沒有提供交易的操作類型和狀態。這些信息對於投資者了解對Novavax投資的潛在影響至關重要。
據報道，Novavax, Inc. [NVAX] 執行副總裁兼首席戰略官伊萊恩·奧哈拉於2024年3月1日參與了一項涉及該公司股票的交易。公告中未披露該交易的具體細節，包括股票數量、股票性質、交易價格和股票總價值。也沒有提供交易的操作類型和狀態。這些信息對於投資者了解對Novavax投資的潛在影響至關重要。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息